Literature DB >> 26274806

Menstrual cycle phase and single tablet antiretroviral medication adherence in women with HIV.

Nancy A Hessol1, Susan Holman2, Howard Minkoff3, Mardge H Cohen4,5, Elizabeth T Golub6, Seble Kassaye7, Roksana Karim8, Oluwakemi Sosanya9, Christopher Shaheen10, Zaher Merhi11.   

Abstract

Suboptimal adherence to antiretroviral (ARV) therapy among HIV-infected individuals is associated with increased risk of progression to AIDS and the development of HIV resistance to ARV medications. To examine whether the luteal phase of the menstrual cycle is independently associated with suboptimal adherence to single tablet regimen (STR) ARV medication, data were analyzed from a multicenter cohort study of HIV-infected women who reported regular menstrual cycles and were taking an STR. In a cross-sectional analysis, suboptimal adherence to an STR among women in their follicular phase was compared with suboptimal adherence among women in their luteal phase. In two-way crossover analyses, whereby the same woman was assessed for STR medication adherence in both her follicular and luteal phases, the estimated exact conditional odds of non-adherence to an STR was measured. In adjusted logistic regression analysis of the cross-sectional data (N=327), women with ≤12 years of education were more than three times more likely to have suboptimal adherence (OR=3.6, p=.04) compared to those with >12 years of education. Additionally, women with Center for Epidemiological Studies Depression Scale (CES-D) scores ≥23 were 2.5-times more likely to have suboptimal adherence (OR=2.6, p=.02) compared to those with CES-D scores <23. In conditional logistic regression analyses of the crossover data (N=184), having childcare responsibilities was associated with greater odds of ≤95% adherence. Menstrual cycle phase was not associated with STR adherence in either the cross-sectional or crossover analyses. The lack of association between phase of the menstrual cycle and adherence to an STR in HIV-infected women means attention can be given to other more important risk factors for suboptimal adherence, such as depression, level of education, and childcare responsibilities.

Entities:  

Keywords:  HIV; medication adherence; menstrual phase; women

Mesh:

Substances:

Year:  2015        PMID: 26274806      PMCID: PMC4713239          DOI: 10.1080/09540121.2015.1069787

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  35 in total

1.  Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring.

Authors:  J H Arnsten; P A Demas; H Farzadegan; R W Grant; M N Gourevitch; C J Chang; D Buono; H Eckholdt; A A Howard; E E Schoenbaum
Journal:  Clin Infect Dis       Date:  2001-09-05       Impact factor: 9.079

Review 2.  The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench.

Authors:  Melanie C Bacon; Viktor von Wyl; Christine Alden; Gerald Sharp; Esther Robison; Nancy Hessol; Stephen Gange; Yvonne Barranday; Susan Holman; Kathleen Weber; Mary A Young
Journal:  Clin Diagn Lab Immunol       Date:  2005-09

Review 3.  Women and vulnerability to HAART non-adherence: a literature review of treatment adherence by gender from 2000 to 2011.

Authors:  Cathy M Puskas; Jamie I Forrest; Surita Parashar; Kate A Salters; Angela M Cescon; Angela Kaida; Cari L Miller; David R Bangsberg; Robert S Hogg
Journal:  Curr HIV/AIDS Rep       Date:  2011-12       Impact factor: 5.071

Review 4.  Pathophysiology of premenstrual syndrome and premenstrual dysphoric disorder.

Authors:  Andrea J Rapkin; Alin L Akopians
Journal:  Menopause Int       Date:  2012-06

5.  Retention of women enrolled in a prospective study of human immunodeficiency virus infection: impact of race, unstable housing, and use of human immunodeficiency virus therapy.

Authors:  N A Hessol; M Schneider; R M Greenblatt; M Bacon; Y Barranday; S Holman; E Robison; C Williams; M Cohen; K Weber
Journal:  Am J Epidemiol       Date:  2001-09-15       Impact factor: 4.897

6.  Retention and attendance of women enrolled in a large prospective study of HIV-1 in the United States.

Authors:  Nancy A Hessol; Kathleen M Weber; Susan Holman; Esther Robison; Lakshmi Goparaju; Christine B Alden; Naoko Kono; D Heather Watts; Niloufar Ameli
Journal:  J Womens Health (Larchmt)       Date:  2009-10       Impact factor: 2.681

7.  Effects of the menstrual cycle on mood, neurocognitive and neuroendocrine function in healthy premenopausal women.

Authors:  C S Symonds; P Gallagher; J M Thompson; A H Young
Journal:  Psychol Med       Date:  2004-01       Impact factor: 7.723

8.  Depressive symptoms and AIDS-related mortality among a multisite cohort of HIV-positive women.

Authors:  Judith A Cook; Dennis Grey; Jane Burke; Mardge H Cohen; Alejandra C Gurtman; Jean L Richardson; Tracey E Wilson; Mary A Young; Nancy A Hessol
Journal:  Am J Public Health       Date:  2004-07       Impact factor: 9.308

9.  A health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with early HIV infection.

Authors:  A W Wu; H R Rubin; W C Mathews; J E Ware; L T Brysk; W D Hardy; S A Bozzette; S A Spector; D D Richman
Journal:  Med Care       Date:  1991-08       Impact factor: 2.983

10.  Protease inhibitor levels in hair strongly predict virologic response to treatment.

Authors:  Monica Gandhi; Niloufar Ameli; Peter Bacchetti; Stephen J Gange; Kathryn Anastos; Alexandra Levine; Charles L Hyman; Mardge Cohen; Mary Young; Yong Huang; Ruth M Greenblatt
Journal:  AIDS       Date:  2009-02-20       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.